Immunocore Holdings (IMCR) Other Non-Current Liabilities (2022 - 2026)
Immunocore Holdings (IMCR) posted Other Non-Current Liabilities of $96.6 million for Q3 2025, up 15.06% sequentially from $84.0 million in Q2 2025, and up 3113.71% YoY from $3.0 million in Q3 2024.
Analysis
Immunocore Holdings (IMCR) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Immunocore Holdings has reported Other Non-Current Liabilities for 7 years, with the latest figure at $96.6 million in Q3 2025.
- Quarterly Other Non-Current Liabilities rose 3113.71% year-over-year to $96.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $96.6 million (up 3113.71% YoY) and the FY2023 annual result came in at $978000.0, down 55.85% from the prior year.
- Other Non-Current Liabilities grew to $96.6 million in Q3 2025 per IMCR's latest filing, from $84.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $96.6 million in Q3 2025 and troughed at $76836.6 in Q4 2021.
- A 5-year average of $22.9 million and a median of $2.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Liabilities tumbled 57.83% in 2021, then surged 3919.15% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $76836.6 in 2021, then soared by 74.02% to $133713.8 in 2022, then surged by 631.41% to $978000.0 in 2023, then surged by 207.36% to $3.0 million in 2024, then soared by 3113.71% to $96.6 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $96.6 million, $84.0 million, and $62.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.88 Mn |
| Sep 30, 2025 | 96.60 Mn |
| Jun 30, 2025 | 83.96 Mn |
| Mar 31, 2025 | 62.48 Mn |
| Sep 30, 2024 | 3.01 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 978,000.00 |
| Dec 31, 2022 | 2.22 Mn |